reports
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results ...
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights - ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And Done™ therapy for wet AMD - ARTEMIS enrollment completion expected in 1Q 2026, with topline data anticipated 1H 2027 - LUNA 2-year long-term follow-up data planned in 4Q 2025 - Announced $10 million private placement with Frazier Life Sciences REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM...
Jeff Harsh named new Chief Operating Officer of Advantage Solutions Br...
Jeff Harsh named new Chief Operating Officer of Advantage Solutions Branded Services business segment Strategic results-driven leader with deep CPG experience and connectivity in retail to succeed Dean General, who will remain at Advantage in newly created role ST. LOUIS, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc (NASDAQ: ADV), announced the appointment of Jeff Harsh as the new Chief Operating Officer of its Branded Services business segment, effective Aug. 25. Harsh will join the company’s executive leadership team and report to CEO Dave Peacock. Harsh comes to Advan...
Merus gibt die Finanzergebnisse für das zweite Quartal 2025 bekannt un...
Merus gibt die Finanzergebnisse für das zweite Quartal 2025 bekannt und informiert über die aktuelle Geschäftsentwicklung – Petosemtamab in Kombination mit Pembrolizumab als Erstlinienbehandlung des PD-L1-positiven rezidivierenden/metastasierten Plattenepithelkarzinoms des Kopfes und Halses zeigt in Phase-II-Studie eine Ansprechrate von 63 % bei 43 auswertbaren Patienten und eine Gesamtüberlebensrate von 79 % nach 12 Monaten – Basierend auf dem aktuellen Geschäftsplan des Unternehmens, den vorhandenen Barmitteln und Barmitteläquivalenten, einschließlich des erfolgreichen Börsengangs mit ei...
Merus annonce ses résultats financiers pour le deuxième trimestre 2025...
Merus annonce ses résultats financiers pour le deuxième trimestre 2025 et fait le point sur ses activités - Le pétosemtamab en association avec le pembrolizumab dans un essai de phase 2 mené chez 43 patients atteints d’un CETC r/m PD-L1+ en première intention a permis d’obtenir un taux de réponse de 63 % et un taux de survie globale de 79 % à 12 mois - D’après le plan d’exploitation actuel de la société, la trésorerie et les équivalents de trésorerie existants, notamment le produit brut de 345 millions de dollars réalisé à l’issue d’une offre publique réussie et les titres négociables devr...
Advantage Solutions Reports Second Quarter 2025 Results
Advantage Solutions Reports Second Quarter 2025 Results Strong profitability growth in Experiential and Retailer Services Advancing transformation initiatives to accelerate AI enablement and improved business insights Expecting improved financial performance and cash generation in the second half of the year Reaffirming 2025 guidance ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage,” “Advantage Solutions,” the “Company,” “we,” or “our”), a leading business solutions provider to consumer goods manufacturers and retailers, today re...
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annu...
Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Professor of Genetic Medicine and Board Member of Adverum, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Wednesday, August 13, 2025 at 9:00am EDT. A live webcast of the fireside chat...
Merus to Present at the Canaccord Genuity 45th Annual Growth Conferenc...
Merus to Present at the Canaccord Genuity 45th Annual Growth Conference UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 1:30 p.m. ET. The webcast of the presentation will be conte...
- Jacob Mekhael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
Merus Announces Financial Results for the Second Quarter 2025 and Prov...
Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update - Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 63% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months - Based on the Company’s current operating plan, existing cash, cash equivalents, including successful public offering raising $345M gross proceeds, and marketable securities expected to fund Merus’ operations at least into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE...
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)...
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that the Company granted non-statutory stock options to two new employees as an inducement award outside the Company’s 2016 Incentive Award Plan (the “Plan”) in accordance with Nasdaq Listing Rule 5635(c)(4). The Co...
- Jonathan Moreland
MERC MERCER INTERNATIONAL INC.
CDXS CODEXIS
PETS PETMED EXPRESS INC.
CLRB CELLECTAR BIOSCIENCES
NHF NEXPOINT CREDIT STRATEGIES FUN
CZWI CITIZENS COMMUNITY BANCORP
LOOP LOOP INDUSTRIES
CHMG CHEMUNG FINANCIAL CORP.
FVCB FVCBANKCORP
FGBI FIRST GUARANTY BANCSHARES
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CMTV COMMUNITY BANCORP INC. VT
DMAC DIAMEDICA THERAPEUTICS INC.
CRDF CARDIFF ONCOLOGY INC
IMRX IMMUNEERING CORP
NSPR INSPIREMD INC
BRCC BRC INC
LEXX LEXARIA BIOSCIENCE CORP
PMNT PERFECT MOMENT LTD.
DMA DESTRA MULTI ALTERNATIVE FUND
NYC NEW YORK CITY REIT
GF INC.
FGEN THE NEW GERMANY FUND
CCIF INC.
CVM FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
CEL-SCI CORPORATION
- Jonathan Moreland
ANTM ANTHEM INC.
SSB SOUTH STATE CORPORATION
SNV SYNOVUS FINANCIAL CORP.
SIGI SELECTIVE INSURANCE GROUP INC.
SFNC SIMMONS FIRST NATIONAL CORPORATION CLASS A
RLI RLI CORP.
PSX PHILLIPS 66
PRGS PROGRESS SOFTWARE CORPORATION
PNFP PINNACLE FINANCIAL PARTNERS INC.
NVCR NOVOCURE LTD.
MTH MERITAGE HOMES CORPORATION
MSCI MSCI INC. CLASS A
MOFG MIDWESTONE FINANCIAL GROUP
FBIZ FIRST BUSINESS FINANCIAL SERVICES
CNC CENTENE CORPORATION
CHTR CHARTER COMMUNICATIONS INC. CLASS A
ALGN ALIGN TECHNOLOGY INC.
UPS UNITED PARCEL SERVICE INC. CLASS B
PETS PETMED EXPRESS INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
PBT PERMIAN BASIN ROYALTY TRUST
LIND LINDBLAD EXPEDITIONS HOLDINGS
KYN KAYNE ANDERSON MLP INVESTMENT CO.
PLBC PLUMAS BANCORP
CZWI CITIZENS COMMUNITY BANCORP
MBIN MERCHANTS BANCORP
PGC PEAPACK-GLADSTONE FINANCIAL CORP.
LOOP LOOP INDUSTRIES
CHMG CHEMUNG FINANCIAL CORP.
FVCB FVCBANKCORP
TLRY TILRAY
TROX TRONOX HOLDINGS PLC
AMTB AMERANT BANCORP (A)
PCB PACIFIC CITY FINANCIAL CORP
DMAC DIAMEDICA THERAPEUTICS INC.
CRDF CARDIFF ONCOLOGY INC
ABSI ABSCI CORP
NSPR INSPIREMD INC
BRCC BRC INC
JMSB JOHN MARSHALL BANCORP INC
PRME PRIME MEDICINE INC
MMC MARSH & MCLENNAN COMPANIES INC.
STRW STRAWBERRY FIELDS REIT INC.
AURX NUO THERAPEUTICS
DMA INC.
MRAI DESTRA MULTI ALTERNATIVE FUND
GF MARPAI
CVM INC.
THE NEW GERMANY FUND
INC.
CEL-SCI CORPORATION
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
PNFP PINNACLE FINANCIAL PARTNERS INC.
FFIN FIRST FINANCIAL BANKSHARES INC
CHTR CHARTER COMMUNICATIONS INC. CLASS A
CDXS CODEXIS
CIVB CIVISTA BANCSHARES
CZWI CITIZENS COMMUNITY BANCORP
MBIN MERCHANTS BANCORP
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
CRDF CARDIFF ONCOLOGY INC
JMSB JOHN MARSHALL BANCORP INC
MMC MARSH & MCLENNAN COMPANIES INC.
Advantage Solutions to Participate in The Canaccord Annual Growth Conf...
Advantage Solutions to Participate in The Canaccord Annual Growth Conference on August 12, 2025 ST. LOUIS, July 30, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ GS: ADV) announced today that Dave Peacock, Chief Executive Officer, and Chris Growe, Chief Financial Officer, will participate in the Canaccord Genuity 45th Annual Growth Conference in Boston on Aug. 12, 2025. A live fireside chat with Dave Peacock will be held at noon EDT. The listen-only webcast can be accessed from the Advantage Solutions website at . For more details, contact your Canaccord Genuity representative...
Home Federal Bancorp, Inc. of Louisiana Reports Results of Operations ...
Home Federal Bancorp, Inc. of Louisiana Reports Results of Operations for the Three Months and Year Ended June 30, 2025 Shreveport, Louisiana, July 29, 2025 (GLOBE NEWSWIRE) -- Home Federal Bancorp, Inc. of Louisiana (the “Company”) (Nasdaq: HFBL), the holding company of Home Federal Bank, reported net income for the three months ended June 30, 2025, of $1.2 million compared to net income of $638,000 reported for the three months ended June 30, 2024. The Company’s basic and diluted earnings per share were $0.39 and $0.38, respectively, for the three months ended June 30, 2025 compared to ...
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase...
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) – Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. control arm – – Onvansertib continues to be well-tolerated and demonstrates a dose dependent response for all endpoints including ORR, early tumor shrinkage and depth of response – – Company will hold a conference call today at 4:30 p.m. ET ...
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Busi...
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update - Appointed Dr. Roger Sidhu as Chief Medical Officer - - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Announced positive data from investigator-initiated trial of onvansertib in combination with paclitaxel in mTNBC at ASCO 2025 - - Cash and investments of $71.0 million as of June 30, 2025, projected runway into Q1 2027 - - Company to hold a conference call today at 4:...
Advantage Solutions Announces Date for its Second Quarter 2025 Financi...
Advantage Solutions Announces Date for its Second Quarter 2025 Financial Results and Conference Call ST. LOUIS, July 25, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ GS: ADV) announced today that it will release financial results for the second quarter at 7 a.m. EDT on Aug. 7, 2025, followed by a conference call at 8:30 a.m. EDT on the same day. The conference call can be accessed live by dialing 1-800-715-9871 for U.S. callers or 1-646-307-1963 for international callers. The conference ID is 5720569. Approximately three hours after the call, a replay will be available by di...
Home Federal Bancorp, Inc. of Louisiana Increases Quarterly Cash Divid...
Home Federal Bancorp, Inc. of Louisiana Increases Quarterly Cash Dividend for 12th Consecutive Year SHREVEPORT, La., July 23, 2025 (GLOBE NEWSWIRE) -- Home Federal Bancorp, Inc. of Louisiana (the “Company”) (NASDAQ: HFBL), the holding company for Home Federal Bank, announced today that its Board of Directors at their meeting on July 23, 2025, declared a quarterly cash dividend of $0.135 per share on the Company’s common stock. The dividend is payable on August 18, 2025, to the shareholders of record at the close of business on August 4, 2025. James R. Barlow, Chairman of the Board, Pre...
CORRECTION - Ad Age lists Advantage Solutions among 2025 Largest Agenc...
CORRECTION - Ad Age lists Advantage Solutions among 2025 Largest Agencies Advantage Solutions ranks No. 18 on the global list ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on July 2 by Advantage Solutions Inc. (NASDAQ: ADV), please note that Advantage’s domestic ranking should have been listed as “12th in the United States” instead of “9th in North America.” It has been removed from the subhead. The corrected release follows: Advantage Solutions (NASDAQ: ADV) ranks as the 12th largest agency company in the United States and No. 18 worldwide, a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.